Results 251 to 260 of about 38,480 (291)
Apixaban in Patients with Atrial Fibrillation [PDF]
New England Journal of Medicine, 2011 Vitamin K antagonists have been shown to prevent stroke in patients with atrial fibrillation. However, many patients are not suitable candidates for or are unwilling to receive vitamin K antagonist therapy, and these patients have a high risk of stroke. Apixaban, a novel factor Xa inhibitor, may be an alternative treatment for such patients.In a double-
Stuart J Connolly +2 more
exaly +11 more sources
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Hämostaseologie, 2012
SummaryApixaban is a potent reversible inhibitor of the activated human coagulation factor X. This new oral anticoagulant has favourable pharmacokinetic and pharmocodynamic properties which include a concentration-dependent anticoagulant effect, good oral bioavailability, balanced elimination and excretion, infrequent drug or food interactions, and the
S, Konstantinides, T, Münzel
openaire +2 more sources
SummaryApixaban is a potent reversible inhibitor of the activated human coagulation factor X. This new oral anticoagulant has favourable pharmacokinetic and pharmocodynamic properties which include a concentration-dependent anticoagulant effect, good oral bioavailability, balanced elimination and excretion, infrequent drug or food interactions, and the
S, Konstantinides, T, Münzel
openaire +2 more sources
Pylephlebitis treated with apixaban
Hospital Practice, 2019Pylephlebitis is a rare condition that is characterized by an infected thrombus of the portal vein system and was traditionally associated with a high mortality rate prior to the introduction of antibiotics. This report details a 77-year-old Chinese male found to have a splenic vein thrombosis, Parvimonas micra bacteremia, and a polymicrobial splenic ...
Graham R. Hale +2 more
openaire +3 more sources
Apixaban-induced leukocytoclastic vasculitis
Adverse Drug Reaction Bulletin, 2020Summary Introduction: Drug-induced vasculitis is a rare adverse drug reaction and the potential to induce such a reaction is often established postmarketing. Leukocytoclastic vasculitis - a subtype of drug-induced vasculitis - often presents itself with palpable purpuric lesions, and often within weeks of initial ...
Esbech, Peter +3 more
openaire +6 more sources
Apixaban: A Review in Venous Thromboembolism
Drugs, 2016Apixaban (Eliquis®) is an oral, direct factor Xa inhibitor that is available for use in the treatment and secondary prevention of venous thromboembolism (VTE). Like other direct oral anticoagulants (DOACs), apixaban has generally predictable pharmacological properties and does not require routine anticoagulation monitoring.
Sarah L. Greig, Karly P. Garnock-Jones
openaire +3 more sources
Improving the Solubility and Bioavailability of Apixaban via Apixaban–Oxalic Acid Cocrystal
Crystal Growth & Design, 2016Apixaban (apx), with a trade name of Eliquis, is a highly selective and efficacious inhibitor of blood coagulation factor Xa. Apixaban has poor solubility in water (0.028 mg/mL at 24 °C) and a relatively low oral bioavailability (about 50% for a single 10 mg dose).
Tong-Bu Lu +5 more
openaire +2 more sources
Half-life of Apixaban During Massive Apixaban Overdose
Journal of Pharmacy Practice, 2023openaire +2 more sources